Immunohistochemistry and Biomarkers in Breast Pathology

The track on "Immunohistochemistry and Biomarkers in Breast Pathology" focuses on the critical role of immunohistochemistry (IHC) and biomarkers in the diagnosis, prognosis, and treatment of breast pathology. This track explores the latest advancements in IHC techniques, including the identification and evaluation of key biomarkers such as hormone receptors (ER, PR), HER2/neu, Ki-67, and other emerging markers. Discussions will revolve around their clinical significance, interpretation challenges, and their impact on therapeutic decision-making. Additionally, this track will delve into novel biomarkers and their potential for risk assessment, predicting treatment response, and guiding personalized treatment strategies. Attendees will gain insights into the evolving landscape of IHC and biomarkers, enhancing their understanding of breast pathology evaluation and patient management.

  • Biomarkers for Breast Cancer Subtyping
  • Emerging Biomarkers in Breast Pathology
  • Immunohistochemistry Techniques and Interpretation
  • Role of Immunohistochemistry in Differential Diagnosis
  • Predictive and Prognostic Biomarkers

Related Conference of Immunohistochemistry and Biomarkers in Breast Pathology

December 14-15, 2023

5th International Conference on Oncology and Cancer

Rome, Italy
February 22-23, 2024

14th World Congress on Breast Cancer

Zurich, Switzerland
March 18-19, 2024

5th Global Summit on Oncology and Hematology

Zurich, Switzerland
March 21-22, 2024

8th Global Meeting on Oncology and Radiology

Paris, France
April 18-19, 2024

24th World Congress on Cancer and Diagnostics

Dubai, UAE

Immunohistochemistry and Biomarkers in Breast Pathology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in